M. Yuneva

Glutaminase as a metabolic target of choice to counter acquired resistance to Palbociclib by colorectal cancer cells

This study shows that combining Palbociclib with Telaglenestat prevents acquired resistance in colorectal cancer cells by counteracting metabolic reprogramming.

SCD inhibition eradicates AML displaying high de novo fatty acid desaturation and synergizes with chemotherapy

SCD inhibition induces AML cell death and synergizes with chemotherapy to prolong survival in murine AML models.

PPAR-delta acts as a metabolic master checkpoint for metastasis in pancreatic cancer

This study shows PPAR-delta drives metabolic reprogramming in pancreatic cancer, promoting metastasis, and its inhibition reduces invasiveness.

Constitutive activation of the PI3K-Akt-mTORC1 pathway sustains the m.3243A>G mtDNA mutation

The paper shows that the m.3243A>G mtDNA mutation activates the PI3K-Akt-mTORC1 pathway, which can be inhibited to reduce mutant mtDNA load and improve cellular function.

Identifying strategies to target the metabolic flexibility of tumours.

The paper identifies compensatory metabolic mechanisms in tumours and shows that targeting these can improve therapeutic outcomes.

Perturbation of the gut microbiota by antibiotics results in accelerated breast tumour growth and metabolic dysregulation

This study shows that antibiotics disrupt the gut microbiota, leading to faster breast tumour growth and metabolic changes in mice.